Courtesy of Benzinga.
Analysts at Cowen & Company initiated coverage on Heron Therapeutics Inc (NASDAQ: HRTX) with a Outperform rating.
The target price for Heron Therapeutics is set to $40.
Heron Therapeutics’ shares rose 3.33 percent to $30.37 in pre-market trading.
Latest Ratings for HRTX
Date | Firm | Action | From | To |
---|---|---|---|---|
Jun 2015 | Cowen & Company | Initiates Coverage on | Outperform | |
Jun 2015 | Leerink Swann | Maintains | Outperform | |
Jun 2015 | Leerink Swann | Maintains | Outperform |
View More Analyst Ratings for HRTX
View the Latest Analyst Ratings
Posted-In: Cowen & CompanyInitiation Analyst Ratings